Ikarian Capital’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-500,000
Closed -$1.55M 185
2025
Q4
$1.55M Buy
+500,000
New +$1.43M 0.12% 115
2022
Q4
Sell
-17,400
Closed -$209K 94
2022
Q3
$209K Buy
+17,400
New +$216K 0.04% 92
2022
Q2
Sell
-14,900
Closed -$129K 164
2022
Q1
$129K Buy
+14,900
New +$144K 0.02% 177
2020
Q1
Sell
-771,100
Closed -$12.1M 162
2019
Q4
$12.1M Buy
+771,100
New +$15.5M 1.95% 10

Other funds holding GOSS

Ikarian Capital's GOSS Position: Q2 2023 in Review

Ikarian Capital sold out of Gossamer Bio (GOSS) in Q2 2023, closing a stake of 6,100 shares — an estimated $7.69K sold.

Ikarian Capital first reported a position in GOSS in Q2 2020 and held it in 12 quarters. The position peaked at $17M in Q3 2021. 99 funds tracked by Wall St. Rank hold GOSS as of Q2 2023.

  • Ikarian Capital reported no remaining Gossamer Bio position as of Q2 2023 after selling out during the quarter.
  • Ikarian Capital sold 6,100 Gossamer Bio shares in Q2 2023, an estimated $7.69K.
  • Ikarian Capital first reported a position in Gossamer Bio in Q2 2020 and held it in 12 quarters.
  • Ikarian Capital's Gossamer Bio position peaked at $17M in Q3 2021.
  • 99 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.